Researchers discovered that neuroestrogen, a hormone produced in the brain, regulates appetite by influencing the ...

Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced updated ...

Axovia Therapeutics Ltd., a biotechnology company developing therapies to address the genetic causes of blindness and obesity ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist ...

The family of medications called GLP-1 receptor agonists includes drugs like Wegovy, Zepbound, Ozempic, Mounjaro and Victoza. They were originally developed to treat type 2 diabetes, which happens ...

The authors use deep mutational scanning to assess the effect of ~6,600 protein-coding variants in MC4R, a G protein coupled receptor associated with obesity. They develop new, more precise approaches ...

The peptide is believed to interact with melanocortin-1 receptors (MC1R), which are primarily associated with the regulation of melanin synthesis. Research indicates that MC1R activation may lead ...

The nicotinic acetylcholine receptors (nAChRs ... broad diversity of nAChR homo-pentamers and hetero-pentamers (Fig. 1). Understanding the atomic structure of the binding site and of its complexes ...

Glucagon-like peptide 1 (GLP-1) receptor agonists are transforming the treatment landscape for type 2 diabetes ( T2D) and obesity, in addition to their cardiovascular benefits. These drugs also ...

The Boston-based biopharma reported positive topline data from the pivotal TRANSCEND trial, which evaluated Imcivree (setmelanotide), a subcutaneous melanocortin-4 ... subtilisin/kexin type 1 (PCSK1), ...

(JAMA Surgery) Palatin Technologies said its investigational oral melanocortin-1 receptor agonist (PL8177) for active ulcerative colitis (UC) significantly improved rates of clinical remission and ...